Know Labs Furthers External Validation of Bio-RFID™ Technology with Study Published in Sensors Journal
May 18 2023 - 8:00AM
Business Wire
Study conducted in collaboration with Mayo
Clinic demonstrates accuracy of Bio-RFID and supports the
technology’s application in non-invasive bio-monitoring
Know Labs, Inc. (NYSE American: KNW), an emerging developer of
non-invasive medical diagnostic technology, today announced the
publication of its first peer-reviewed study in Sensors Journal.
The manuscript titled, Detecting Unique Analyte-Specific Radio
Frequency Spectral Responses in Liquid Solutions—Implications for
Non-Invasive Physiologic Monitoring, describes the
proof-of-principle study of Know Labs’ Bio-RFID technology that
quantified different analytes in vitro, proving a 100% accuracy
rate. Sensors is the leading international, peer-reviewed, open
access journal on the science and technology of sensors.
The publication of the full manuscript comes just one month
after Know Labs announced the study abstract and results via a
press release, which underwent review by the American Physiological
Society (APS) Program Committee before presentation at the 2023 APS
Summit.
“This is a big milestone for us,” said Ron Erickson, CEO and
Chairman at Know Labs. “The first of many peer-reviewed
publications of Know Labs’ research is significant in validating
our Bio-RFID technology on the road towards delivering the first
FDA-cleared, truly non-invasive glucose monitoring device to the
market. We have a lot more firsts on the horizon, and we’re eager
to share what’s next.”
This journal publication contributes to the growing body of
peer-reviewed research that Know Labs is conducting as the company
prioritizes external validation of its Bio-RFID technology in
detecting and measuring glucose and other analytes in the body
non-invasively at high levels of accuracy.
“We’re excited to publish this research in a scientific journal
like Sensors to validate the work being done at Know Labs that is
truly revolutionary,” said James “Andy” Anderson, M.D., Chief
Medical Officer at Know Labs. “Know Labs is one step closer to
bringing its non-invasive glucose monitoring technology to the
masses, and that is something that will change modern medicine as
we know it.”
To learn more about Know Labs and the ongoing series of research
studies being conducted by the company, please visit
https://www.knowlabs.co/research-and-validation.
Mayo Clinic has a financial interest in the technology
referenced in this press release. Mayo Clinic will use any revenue
it receives to support its not-for-profit mission in patient care,
education and research.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the
NYSE American Exchange under the stock symbol “KNW.” The Company’s
technology uses spectroscopy to direct electromagnetic energy
through a substance or material to capture a unique molecular
signature. The Company refers to its technology as Bio-RFID™. The
Bio-RFID technology can be integrated into a variety of wearable,
mobile or bench-top form factors. This patented and patent-pending
technology makes it possible to effectively identify and monitor
analytes that could only previously be performed by invasive and/or
expensive and time-consuming lab-based tests. The first application
of our Bio-RFID technology will be in a product marketed as a
non-invasive glucose monitor. It will provide the user with
real-time information on blood glucose levels. This product will
require U.S. Food and Drug Administration clearance prior to its
introduction to the market.
Safe Harbor Statement
This release contains statements that constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. These statements appear in a number of places in this
release and include all statements that are not statements of
historical fact regarding the intent, belief or current
expectations of Know Labs, Inc., its directors or its officers with
respect to, among other things: (i) financing plans; (ii) trends
affecting its financial condition or results of operations; (iii)
growth strategy and operating strategy; and (iv) performance of
products. You can identify these statements by the use of the words
“may,” “will,” “could,” “should,” “would,” “plans,” “expects,”
“anticipates,” “continue,” “estimate,” “project,” “intend,”
“likely,” “forecast,” “probable,” “potential,” and similar
expressions and variations thereof are intended to identify
forward-looking statements. Investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, many of which are beyond Know
Labs, Inc.’s ability to control, and actual results may differ
materially from those projected in the forward-looking statements
as a result of various factors. These risks and uncertainties also
include such additional risk factors as are discussed in the
Company’s filings with the U.S. Securities and Exchange Commission,
including its Annual Report on Form 10-K for the fiscal year ended
September 30, 2022, Forms 10-Q and 8-K, and in other filings we
make with the Securities and Exchange Commission from time to time.
These documents are available on the SEC Filings section of the
Investor Relations section of our website at www.knowlabs.co. The
Company cautions readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
The Company undertakes no obligation to update any forward-looking
statement to reflect events or circumstances after the date on
which such statement is made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230518005308/en/
For Know Labs Media Inquiries Contact: Matter Health
Laura Bastardi Knowlabs@matternow.com Ph. (603) 494-6667
Know Labs, Inc. Contact: Jordyn Hujar jordyn@knowlabs.co
Ph. (206) 629-6414
Know Labs (AMEX:KNW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Know Labs (AMEX:KNW)
Historical Stock Chart
From Jul 2023 to Jul 2024